Graft-versus-host disease across minor histocompatibility barriers was induced in two different models by transplanting allogeneic bone marrow and spleen cells into irradiated H-2-compatible recipient mice. In this report, we show that administration of peptides with high binding affinity for the respective class II major histocompatibility complex molecules after transplantation is capable of preventing the development of graft-versus-host disease in two different murine models. The peptides used were myelin basic protein residues 1 through 11 with alanine at position 4 (Ac 1-1 1[4A]) NTIGEN-SPECIFIC T-CELL activation occurs when the T-cell receptor (TCR) recognizes antigenic peptide fragments bound to self molecules encoded by the major histocompatibility complex (MHC).' CD8+ T cells usually recognize peptides complexed to class I MHC molecules. In contrast, CD4+ T cells recognize peptides in association with class I1 molecules. The structure of the class I1 binding site has recently been determined by x-ray crystallography.' Each MHC molecule possesses a single peptide-binding site, showing a certain degree of specificity. Two groups have eluted and characterized self-peptides bound to murine class I1 MHC molecules I-Ab, LEb, and l-Ad by a combination of high-performance liquid chromatography and amino-acid sequencing3 or by tandem mass spectroscopy! Cellular proliferation assays and direct binding studies have shown competition among peptides for binding to class I1 molecules in vitro.'" In vivo competition was first shown in the hen egg lysozyme (HEL) system. Administration of class 11-binding competitor peptides in vivo specifically inhibited the capacity of lymph node cells to present antigen to class 11-restricted T cells.x On the basis of these findings, it has been possible to design peptide-mediated immunotherapy (interfering with the MHC-peptide-TCR triad) for the prevention of distinct T-cell-mediated autoimmune diseases, namely, experimental allergic encephalomyelitis (EAE) in 
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(PWJ X SJL)FI and SJL mice, myosin-induced carditis, and, most recently, the development of autoimmune diabetes in nonobese diabetic m i~e . ' .~.~"~ Unlike autoimmune diseases, graft-versus-host disease (GVHD) is caused by transplanted allogeneic T cells.I4 In bone marrow transplantation (BMT) across minor histocompatibility (mH) barriers, allogeneic T cells recognize multiple mH antigens of the host as "nonself."1'-'' Accumulated evidence from recent work"-26 indicates that mH antigens are genetically polymorphic peptides, derived from a variety of cellular proteins that are subsequently presented by MHC molecules. To test this concept further, we investigated whether class 11-binding competitor peptides could prevent GVHD. Two different strain combinations (PLIJ + B LO.PL, H-2"; SJL + BlOS, H-2") were selected. The experimental group design for the studies is outlined in Table 1 . Ac 1-1 1, the acetylated N-terminal 1 -1 1 peptide of myelin basic protein (MBP), and its analogs are well characteri~ed.~.~.'~.~~ Residue 4 influences binding of the peptide to I-A", whereas residues 3 and 6 are important for T-cell interaction. Substitution at position 4 (Lys -+ Ala) creates a peptide analog, Ac 1-1 1[4AJ, that binds to I-A" 10-to 100-fold better than the original peptide.' The epitope 35-47 of MBP, which is recognized in association with I-E", was chosen as a binding peptide for I-E"." The KM-core extension peptide, based on the antigenic core sequence of ovalbumin 323-339, binds strongly to LA', is resistant to serum proteases, and is highly effective in inhibiting EAE induction by proteolipid protein (PLP 139-151) in SJL mice." The data in this report show for the first time that GVHD can be prevented by administration of peptides with high affinity for class I1 MHC molecules and that the mechanism of prevention is MHC-associated.
MATERIALS AND METHODS

Animals and transplantation.
Female PLIJ, B10.PL (both H-2") and SJL (H-2') mice were purchased from The Jackson Laboratories (Bar Harbor, ME). BIOS (H-2') female mice were bred in our own facility. SJL and BIOS mice express class I1 I-As (AdAB') only; I-Ea is deleted.z9 GVHD was induced by transplanting 10 X IO6 allogeneic BM and 50 x lo6 allogeneic spleen cells into sublethally irradiated (560 R) H-2 identical recipient mice.30 Recipient mice were 12 weeks old at the time of transplantation. The experimental group design is outlined in Assessment of GVHD. Skin biopsies were examined by two independent observers for histologic evidence of GVHD. Epidermal dyskeratotic cells (EDC; individual cell death as defined by nuclear pyknosis and cytoplasmic hypereosinophilia) and vacuolated cells (basal epithelial cells with vacuolar degeneration of the cytoplasm) were quantitated as previously de~cribed.~' Given 95% confidence intervals for groups B and D, GVHD prevention in any particular mouse was defined as histologic changes identical to syngeneic controls.
PCR analysis. Engraftment of donor BM was documented by PCR amplification of a polymorphic microsatellite region within the interleukin-5 (IL-5) gene. Primer sequences are as follows: 5'-CATATCCAGC-3'.'' These sequences are available from EMBLl Gen-BankDDBJ (Bethesda, MD) under the accession numbers X75904 and X75905. Oligonucleotides were synthesized on a 391 DNA synthesizer (Applied Biosystems, Foster City, CA) and were purified. DNA was prepared from spleen cells 100 days after transplantation according to standard protocols.'' PCR reaction conditions were the following: 25 pL total volume with 200 ng genomic DNA as template, 15 pmol primers, 0.4 mmoln each dNTP, 10 nmoVL Tris-C1 (pH 8.3), 50 mmol/L KCl, 1 mmol/L MgC12, and 1.0 U AmpliTAQ DNA-polymerase (Perkin Elmer, Emeryville, CA). Amplification was performed for 30 cycles (1 minute of denaturation at 94"C, 1 minute of annealing at 55"C, and l minute of elongation at 72°C.
Peptides. Peptides were synthesized by standard FMOC chemistry as previously described.6 All peptides were 95% to 99% pure, as determined by high-performance liquid chromatography, and were checked by amino-acid analysis and mass spectroscopy. Sequences are given in single letter codes: Ac Table 1 ). Control mice received either phosphate-buffered saline (PBS) or a nonbinding control peptide (MBP 89-101 for I-A" and I-E"; HEL 46-61 for I-AS)."" Syngeneic control mice received PBS. For the first 3 weeks after transplantation, peptides were injected in PBS intraperitoneally (IP) daily, based on published data of the half-life of peptide-class Il complexes being between 5 and 38 hours in live antigen-presenting cells.'3." The frequency of injections was tapered to 3 times per week for the following 2 weeks and to 2 times per week for another 2 weeks. Once a week, peptides were administered with incomplete Freund's adjuvant (FA) as a depot dose. Treatment was discontinued after 7 weeks. Each injection contained 100 pg (60 to 80 nmol) of each peptide, except for control peptide MBP 89-101, which contained 200 pg ( In two additional experiments, T-cell proliferation assays were performed from transplanted B 1O.PL mice after 21 days of daily peptide treatment and after administration of the peptides with IFA once a week. Culture medium was RPM1 1640 supplemented with 1% fresh normal mouse serum, 2 mmom glutamine, 50 pmol/L 2-mercaptoethanol, 100 UlmL penicillin, and 100 pg/mL streptomycin.
Secondary mixed lymphocyte cultures. Responder spleen cells were harvested from B1O.PL mice 21 days after prior immunization with irradiated (3,000 R) 50 X lo6 PLlJ spleen cells. Responder cells (5 X 10') were plated with different amounts (2.5 to 10 X 10') of irradiated PLlJ stimulator cells in the presence or absence of various peptides (20 pglwell). After 96 hours of incubation, cultures were pulsed with 1 pCi of ['HI-thymidine for an additional 16 hours. Results are mean counts per minute (cprn) from triplicate cultures.
Inhibition of T-celf priming. PLlJ mice were immunized subcutaneously in the hind footpads with 3.5 nmol whole ovalbumin (OVA; Sigma, St Louis, MO) emulsified in complete Freund's adjuvant or with a mixture of 3.5 nmol OVA and Ac 1-1 1 [4A], or MBP 35-47, or MBP 89-101, or KM core at the molar excess of peptide indicated. After 9 days, T-cell proliferative responses to whole OVA from inguinal lymph nodes were performed as described previously." [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] prevent GVHD in the PUJ 4 BIO.PL (H-2") system. Mice were followed up for 100 days after BMT for evidence of GVHD. Skin biopsy specimens were taken 30 days after transplantation during peptide therapy and on day 70 after transplantation, 21 days after peptide therapy had been stopped. Figures 1A and B show GVHD-specific skin changes on day 30 and day 70 in the PL/J "* B 10.PL system. Data points represent individual mice and their values of dyskeratotic cells (EDC) per millimeter of skin and vacuolated cells per millimeter of skin in the different experimental groups. Data pooled from two identical experiments showed that the incidence of histologic GVHD on day 30 was 16 of 16 in control groups B (PBS) and C (nonbinding peptide) and was 0 of 14 in group D (syngeneic controls). Given 95% confidence intervals for groups B and D, GVHD prevention in any particular mouse was defined as histologic changes identical to syngeneic controls and is represented graphically as a dashed box (Fig 1A  and B) . No prevention was found with the nonbinding peptide MBP 89-101 (n = 16). However, GVHD was prevented The group design is outlined in Fig 1A) . Figure 2 shows representative skin biopsy specimens from animals of the experimental groups A through D. Skin biopsy specimens from control-transplanted mice of groups B and C that were treated with PBS or MBP 89-101 show prominent EDC and vacuolated cells in the epidermis with diffuse basal cell layer hyperplasia and infiltrates of superficial dermal mononuclear cells. Figure 2A depicts a biopsy specimen from a mouse that received Ac 1-1 1[4A] and MBP 35-47 and did not develop GVHD, a finding identical to the histology of a syngeneic control mouse (Fig 2D) . The effect of the binding peptides was transient in some mice and permanent in others. After discontinuation of treatment GVHD recurred in 4 of 18 mice of group A, when they were tested 70 days posttransplant ( Fig 1B) ; 6 of 18 mice remained without evidence of GVHD (P < .05). Documentation of engraftment. PCR analysis was performed 100 days posttransplant to document long-term engraftment of allogeneic BM cells. DNA polymorphism based on length variation in tandem repeat sequences of a microsatellite in the murine IL-5 gene3' was used as marker to differentiate between donor-derived (PWJ) and recipient (B1O.PL) cells. Figure 3 depicts one representative analysis on an ethidium bromide-stained 2% agarose gel. Long-term engraftment of donor-derived cells was shown in all allogeneic mice by PCR analysis.
RESULTS
Ac I-11[4A] and MBP
KM-core extension peptide prevents GVHD in the SJL + BI0.S (H-2") system, To determine whether the above results were a unique property of the peptides Ac 1-1 1 [4A] and MBP 35-47 or whether a similar mechanism might operate in other H-2-identical donor-recipient strain combinations as well, an additional strain combination was chosen. KM-core extension peptide was selected for its well-characterized high-binding affinity for I-As and for its resistance to serum proteases." Moreover this peptide is structurally unrelated to the MBP. Data from two similar experiments showed that the incidence of GVHD on day 30 and day 70 was 14 of 14 in mice treated with PBS and 13 of 13 in mice treated with the nonbinding control peptide HEL 46-61. However, in mice that received KM-core, the incidence of GVHD was 10 of 16 (62.5%) on day 30 and 11 of 16 (68.8%) on day 70 posttransplant. Fig 4A) . Moreover, the IL-2 response in groups B and C could be completely restored by exogenous addition of Ac 1-1 1 [4A] to the assay. Ac 1-1 1 [4A] could be detected on peritoneal macrophages with this assay as long as 2 to 4 hours after IP injection (data not shown).
Immunogenicity of the competitor peptides. AS another important step in our understanding of the mechanism of in vivo prevention, we have tested whether the soluble peptides in F A are able to induce proliferative T-cell responses against themselves. For these assays, nonirradiated mice from donor strains were chosen, because donor T cells are responsible for inducing GVHD in transplanted animals. A total of 150 nmol of Ac 1-11[4A] or MBP 35-47 emulsified in F A was injected IP into nonirradiated PWJ mice. Similarly, 150 nmol of KM core in IFA was injected into nonirradiated SJL mice. T-cell proliferation assays showed no proliferative response to Ac 1-1 1 [4A] or MBP 35-47 (Fig 4B) . In contrast, however, KM core in IFA was found to be highly immunogenic (Fig 4B) . The implication of these findings on differential mechanisms of prevention in the H-2" and H-2s systems are discussed below. It was then asked whether daily administration of Ac 1-1 1[4A] and MBP 35-47 according to the treatment schedule would induce a proliferative T-cell response in transplanted B 1O.PL mice. In two similar experiments, no proliferative T-cell response to either peptide could be detected (Fig 4C) .
Selective in vitro inhibition of secondary mixed lymphocyte reaction (MLR). We then determined whether T-cellmediated proliferative responses against mH antigens could also be inhibited in vitro. In secondary MLR, Ac 1-1 1 [4A], which binds to I-A", or MBP 35-47, which binds to I-E", inhibited the proliferative response of responder spleen cells from primed B 1O.PL mice to irradiated PWJ stimulator cells by 60% or 43%, respectively (Fig 5A) . Inhibition by class IIbinding peptides was MHC-associated, because the control peptides KM core and MBP 89-101, which bind with high affinity to a different allele (I-K):'' failed to block the response.
MHC-specijc inhibition of T-cell priming to whole OVA. After the observation of inhibition of T-cell responses to mH antigens in vitro, we investigated whether in vivo T-cell responses could be inhibited in a similar fashion. We decided to test whether priming to a native structurally nonrelated, nonself protein (OVA) in PWJ mice could be inhibited by coimmunization of OVA with Ac 1-11[4A] or MBP 35-47 at a molar excess of competitor peptide over OVA of 1: 1, 25: 1, and 1OO:l. As for coimmunization with Ac 1-1 1[4A], maximum inhibition (77.6% to 96%) was already found at the ratio of 1: 1 (Fig 5B) . For MBP 35-47, no inhibition was found at a ratio of 25: 1 (data not shown); at a ratio of 100: 1, maximum inhibition of OVA-specific T-cell proliferation ranged from 45.9% to 51.4%. Specificity controls included the nonbinding control peptide 89-101, which did not block T-cell responses at any of the molar ratios tested.
DISCUSSION
The molecular basis of antigen recognition by T cells has been intensely studied in recent years, and the various pathways of T-cell activation and functional specialization have been defined. Consequently, it is now possible to delineate various strategies for intervention with allorecognition in the context of BMT, namely, interference with TCR-peptide-MHC recognition, blocking of T-cell costimulation, differential activation of CD4' T cells by antigen-presenting cells, and interference with recruitment of T cells mediated through homing receptors." Previous studies have shown T-cell subsets can be responsible for the induction of GVHD across mH barriers. Although one purified subset of T cells may be sufficient to initiate GVHD," a combination of CD8' and CD4' T cells induces a much more severe form of GVHD in a variety of experimental strain a conclusion that is consistent with the classical paradigm that the cellular response to alloantigens involves both class l-restricted and class 11-restricted T cells. Furthermore, isolation of T cells from the skin of mice with GVHDIX and clonal analysis of murine GVHD on days 14 and 50 after transplant" have that both CD4' 18-22. 36 and CD8' ?1).?1.3h.37 SCHLEGEL ET AL shown the importance of CD4' T cells in the early and later phases of GVHD.
In this series of studies, we focused on the interaction of T cells with antigens presented by class I1 MHC molecules. Results of four independent experiments in two distinct murine models of GVHD across mH barriers showed that class 11-binding competitor peptides can be used to prevent GVHD in vivo. The mechanism of prevention was MHC-associated. Binding of the competitor peptide to the class I1 molecule was a prerequisite for prevention in both systems. Nonbinding control peptides (Fig IA and IB) or the administration of IFA alone (data not shown) did not prevent the induction of GVHD. Thus, the mechanism of prevention in both model systems is mediated by interference with T-cell recognition of host peptide-MHC complexes. Furthermore, PCR analysis of transplanted mice showed that prevention of GVHD was not an artefact related to regrowth of autologous BM.jX All allogeneic mice showed long-term engraftment of donorderived cells.
GVHD across mH barriers is caused by donor T cells recognizing mH antigens of the host as "nonself."'6 Over 40 murine mH loci have been defined,26 and almost every chromosome, including the mitochondrial genome, carries at least Minor antigens share unique features. Whereas MHC antigens are recognized by both T and B cells, responses to mH antigens are strictly T-cell-mediated, and their recognition is MHC-restricted.2h.3" Detectable T-cell re- Experimental models of autoimmune diseases in which class II-binding peptides have been used can be assigned to two categories, based on the presence or absence of structural homology between the inhibiting peptide and the diseaseinducing antigenslpeptides. In systems where the inhibitor peptide is closely related to the antigenic peptide, antigenspecific mechanisms in addition to interference with TCRpeptide-MHC recognition must be considered. These additional regulatory mechanisms include induction of crossreactive T-cell t~lerance,~' induction of regulatory suppressor T cells,' alteration in the signalling pathway through TCR occupancy leading to anergy,44 or a shift in the lymphokine However, in both murine models of GVHD described in this manuscript, MHC-specific mechanisms rather than antigen-specific mechanisms must be considered, because competitor peptides and multiple endogenous self peptides are nonhomologous. Competitive blockade of class I1 molecules in and immunodominance",4' have been invoked as MHC-specific mechanisms of inhibiting Tcell activation. Using a panel of T-cell hybridomas generated from P2M-l-knock-out mice, GuCry et al."' have recently presented evidence that exogenous MHC antagonists can inhibit constitutive presentation of an endogenous, naturally processed self epitope. Our results show that partial occupancy of class II-binding sites was sufficient to inhibit the development of GVHD. Furthermore, it was shown that Ac 
